Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b

Journal of Chemotherapy

Volumn 17, Issue 6, 2005, Pages 674-678

  Bex, A ^a   Kerst, J ^a   Mallo, H ^a   Van Tinteren, H ^a   Horenblas, S ^a   De Gast, G C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Immunotherapy; Metastatic; Renal cell carcinoma; Temozolomide

Indexed keywords

ALPHA2B INTERFERON; GRANISETRON; METOCLOPRAMIDE; PEGINTERFERON ALPHA2B; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVALUATION; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 30744448400     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.6.674     Document Type: Article

References (32)

1. Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Oncol 2001; 19(2):98-102.
2. Bleumer I, Oosterwijk E, De Mulder PH, Mulders PFA. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44:65-75.
3. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004; 10((Suppl.)):6302s-6303s.
4. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003; 14(12):1715-1721.
5. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancers. Clin Cancer Res 1997; 3(7):1093-1100.
6. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65(2):287-291.
7. Adonizio CS, Babb JS, Maiale C, Huang C, Donahue J, Millenson MM et al. Temozolomide in non-small-cell lung can-cer: preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer 2002; 3(4):254-258.
8. Raymond E, Izbicka E, Soda H, Gerson SL, Dugan M, von Hoff DD. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 1997; 3:1769.
9. Bafaloukos D, Tsoutsos D, Fountzilas G, Linardou H, Christodoulou C, Kalofonos HP et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 2004; 14(4):289-294.
10. Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003; 8(1):69-75.
11. Reni M, Mason W, Zaja F, Perry J, Franceschi E. Bernardi D et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004; 40(11):1682-1688.
12. Park DK, Ryan CW, Dolan ME, Vogelzang NJ, Stadler WM. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 2002; 50:160-162.
13. Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S et al. A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2004; 24(1):37-41.
14. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88:1044-1011.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3):205-216.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10(1):1-10.
17. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1):289-296.
18. Tano K, Shiota S, Collier J, Foote RS, Mitra S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Nat Acad Sci USA 1990; 87:686-690.
19. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosurea: a Southwest Oncology Group Study. J Clin Oncol 1998; 16:3310-3315.
20. Dumenco LL, Warman B, Hatzoglou M, Lim IK, Abboud SL, Gerson SL. Increase in nitrosurea resistance in mammalian cells by retrovirally mediated gene transfer of bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res 1989; 49:6044-6051.
21. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-1354.
22. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10(15):4933-4938.
23. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S et al. clinical trial substantiates the predictive value of O-6-methylguanine-DNA- methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10(6):1871-1874.
24. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I et al. Phase I trial of temozolomide using an extended continous oral schedule. Cancer Res 1998; 58(19):4363-4367.
25. Willson JK, Haaga JR, Trey JE, Stellato TA, Gordon NH, Gerson SL. Modulation of O6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J Clin Oncol 1995; 13:2301-2308.
26. Spiro TP, Gerson SL, Liu L, Majka S, Haaga J, Hoppel CL et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999; 59:2402-2410.
27. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O (6) -alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001; 7(8):2309-2317.
28. Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 1997; 40:266-272.
29. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncol 2002; 4(1):39-43.
30. Trent JC, Beach J, Burgess MA, Papadopoulos N, Chen LL, Benjamin RS et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98(12):2693-2699.
31. Barvaux VA, Ranson M, Brown R, McElhinney RS, McMurry TB, Margison GP. Dual repair modulation reverses temozolomide resistance in vitro. Mol Cancer Ther 2004; 3(2):123-127.
32. Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, Dahiya R. DNA mismatch repair genes in renal cell carcinoma. J Urol 2003; 169(6):2365-2371.